Valuation: AstraZeneca PLC

Market Cap 25TCr 22TCr 20TCr 19TCr 35TCr 24,33500Cr 36TCr 2,41000Cr 94TCr 12,19600Cr 95TCr 93TCr 40,37500Cr P/E 2026 *
21x
P/E 2027 * 18.3x
Enterprise Value 27TCr 23TCr 22TCr 20TCr 38TCr 26,18400Cr 38TCr 2,59300Cr 1,01100Cr 13,12200Cr 1,02700Cr 1,00500Cr 43,44300Cr EV / Sales 2026 *
4.33x
EV / Sales 2027 * 3.98x
Free-Float
96.63%
Yield 2026 *
2.03%
Yield 2027 * 2.15%
1 day-11.87%
Current year+1.81%
Current year 152.4
Extreme 152.4
166.3
1 year 124.15
Extreme 124.15
166.3
3 years 111
Extreme 111
166.3
5 years 94.29
Extreme 94.29
166.3
10 years 47.72
Extreme 47.715
166.3
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-11.84%0.00% - - 25TCr
-1.53%+4.21%+78.59%+129.05% 1,14100Cr
-1.09%+3.03%+50.98%+61.35% 66TCr
-0.53%+5.53%+26.56%+76.28% 47TCr
+1.20%+2.62%+41.69%+46.21% 37TCr
-0.61%+2.10%+23.43%+40.38% 30TCr
+0.32%+3.25%+0.94%+13.25% 25TCr
-1.67%+4.14%+46.78%+66.91% 24TCr
-1.10%-0.70%-14.31%-53.04% 21TCr
-1.54%+5.27%+22.48%+91.49% 18TCr
Average -1.88%+4.10%+30.79%+52.43% 42.46TCr
Weighted average by Cap. -1.59%+4.31%+44.67%+72.70%

Financials

2026 *2027 *
Net sales 6.32TCr 5.42TCr 5.05TCr 4.64TCr 8.71TCr 6,05200Cr 8.88TCr 60TCr 23TCr 3,03300Cr 24TCr 23TCr 10,04100Cr 6.68TCr 5.72TCr 5.34TCr 4.9TCr 9.21TCr 6,39500Cr 9.39TCr 63TCr 25TCr 3,20500Cr 25TCr 25TCr 10,61100Cr
Net income 1.21TCr 1.03TCr 964.22Cr 884.76Cr 1.66TCr 1,15500Cr 1.7TCr 11TCr 4.46TCr 58TCr 4.53TCr 4.43TCr 1,91600Cr 1.37TCr 1.17TCr 1.1TCr 1.01TCr 1.89TCr 1,31200Cr 1.93TCr 13TCr 5.07TCr 66TCr 5.15TCr 5.04TCr 2,17700Cr
Net Debt 1.93TCr 1.65TCr 1.54TCr 1.42TCr 2.66TCr 1,84900Cr 2.71TCr 18TCr 7.14TCr 93TCr 7.26TCr 7.1TCr 3,06800Cr 1.17TCr 997.65Cr 930.83Cr 854.12Cr 1.6TCr 1,11500Cr 1.64TCr 11TCr 4.3TCr 56TCr 4.38TCr 4.28TCr 1,85000Cr
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
163.97USD
Average target price
212.30USD
Spread / Average Target
+29.47%

Quarterly revenue - Rate of surprise